From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

Failure to ensure that everyone has access to prevention options to protect oneself from HIV acquisition, has resulted in at ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...